Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
R. S. Simmonds, J. Naidoo, C. L. Jones & J. R. Tagg. (1995) The Streptococcal Bacteriocin-like Inhibitory Substance, Zoocin A, Reduces the Proportion of Streptococcus mutans in an Artificial Plaque. Microbial Ecology in Health and Disease 8:6, pages 281-292.
Read now
Read now
C. J. Skilton & J. R. Tagg. (1992) Production by Streptococcus sanguis of Bacteriocin-like Inhibitory Substances (BLIS) with Activity Against Streptococcus rattus. Microbial Ecology in Health and Disease 5:5, pages 219-226.
Read now
Read now
Articles from other publishers (5)
John R. Tagg, Liam K. Harold, Rohit Jain & John D. F. Hale. (2023) Beneficial modulation of human health in the oral cavity and beyond using bacteriocin-like inhibitory substance-producing streptococcal probiotics. Frontiers in Microbiology 14.
Crossref
Crossref
Flavia Indrio, Giuseppe Riezzo, Francesco Raimondi, Antonio Di Mauro & Ruggiero Francavilla. (2013) Microbiota Involvement in the Gut–Brain Axis. Journal of Pediatric Gastroenterology and Nutrition 57, pages S11-S15.
Crossref
Crossref
John R. Tagg & Karen P. Dierksen. (2003) Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention. Trends in Biotechnology 21:5, pages 217-223.
Crossref
Crossref
M.L. Chikindas, J. Novák, P.W. Caufield, K. Schilling & J.R. Tagg. (1997) Microbially-produced peptides having potential application to the prevention of dental caries. International Journal of Antimicrobial Agents 9:2, pages 95-105.
Crossref
Crossref
Robin S Simmonds, Warren J Simpson & John R Tagg. (1997) Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. Gene 189:2, pages 255-261.
Crossref
Crossref